DXR

DAXOR CORP - 10-Q Summary (Period Ended June 30, 2008)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2008, and the six months ended on that date. DAXOR Corporation operates two primary business segments: Equipment Sales and Related Services (Blood Volume Analyzer and Volumex kits) and Cryobanking and Related Services (blood and semen storage). The company also maintains a significant investment portfolio, which serves as a critical source of income to offset operating losses.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Revenue Decline: Consolidated operating revenues decreased by 7.01% ($73,700) compared to the prior year. This was primarily due to selling only three Blood Volume Analyzers in the first half of 2008 versus five in 2007. However, revenue from Volumex kit sales increased by 18.32% due to a higher installed base of analyzers (56 units vs. 50 units).
• Investment Income Surge: Net income increased significantly (63.4%) driven by investment activities. Realized gains on the sale of securities jumped 146.31% to $8.48 million. Mark-to-market gains on short positions contributed $2.14 million.
• Cash Position: Cash and cash equivalents dropped drastically from $2.03 million at the end of 2007 to $21,246 at June 30, 2008. This was due to net cash used in operating activities ($3.0 million) and financing activities ($319,509), partially offset by net cash provided by investing activities ($1.3 million).
• Expense Management: Total consolidated operating expenses decreased slightly by 0.59%, largely due to a $62,597 reduction in payroll and related expenses.

Guidance, Outlook, Risks, and Unusual Items

• Dividend Declaration: The Board declared a quarterly dividend of $0.25 per share, payable August 27, 2008. This is the first dividend since 1996. Management intends to maintain this policy if net income permits, partly to mitigate Personal Holding Company (PHC) tax liabilities.
• Regulatory Risk (CMS Policy): A significant Centers for Medicare and Medicaid Services (CMS) policy change effective January 1, 2008, eliminated separate reimbursement for diagnostic radiopharmaceuticals (Volumex) for outpatient services. Hospitals must now absorb the cost. Management cannot currently quantify the full impact on future revenues, though industry groups are attempting to reverse the ruling.
• PHC Tax Liability: The company is classified as a Personal Holding Company. Undistributed PHC income for the six months ended June 30, 2008, was approximately $8.2 million, resulting in an estimated tax provision of $400,000. Management plans to reduce this liability via dividends or realizing losses on securities.
• Liquidity: While the company has substantial assets in its investment portfolio ($77.8 million), liquid cash is low. The portfolio is essential for funding operations and R&D. Management noted that terms for raising additional capital were recently deemed disadvantageous.

Investor Verification Checklist

• Cash Runway: Verify the sustainability of operations given the cash balance of only $21,246 against ongoing operating losses of ~$2.5 million per six months.
• Investment Volatility: Assess the reliance on investment gains ($11.7 million) to generate net income, noting that operating segments remain unprofitable.
• Reimbursement Impact: Monitor the long-term effect of the CMS reimbursement policy change on Volumex kit sales volume and pricing power.
• Dividend Sustainability: Confirm if the declared dividend is sustainable without eroding the investment portfolio or increasing debt, especially given the PHC tax implications.
• Concentration Risk: Note that three hospital customers accounted for 49.15% of Blood Volume Kit sales, and the investment portfolio is heavily concentrated in electric utilities.